Synergy Between PCI With TAXUS and Cardiac Surgery: SYNTAX Extended Survival
Completed
- Conditions
- Coronary Artery Disease
- Registration Number
- NCT03417050
- Lead Sponsor
- Erasmus Medical Center
- Brief Summary
An investigator-driven, retrospective study to compare long-term survival-data (10-year follow-up) of patients with coronary artery disease (CAD), previously enrolled in the SYNTAX trial, who were randomized to percutaneous coronary intervention (PCI) using a paclitaxel (TAXUS) drug-eluting-stent (DES) or coronary artery bypass grafting (CABG).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 2636
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Long-term survival status 10-year All-cause death
- Secondary Outcome Measures
Name Time Method Cause of death 10-year Cause-specific death, separated in cardiovascular and non-cardiovascular death with specific causes for cardiovascular deaths.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie paclitaxel's efficacy in drug-eluting stents for coronary artery disease?
How does 10-year survival with paclitaxel DES compare to CABG in patients with complex coronary artery disease?
Which biomarkers predict long-term outcomes in SYNTAX trial participants randomized to PCI or CABG?
What are the late adverse events associated with paclitaxel DES versus CABG in coronary artery disease patients?
How does paclitaxel DES performance compare to other drug-eluting stents in CAD patients with high SYNTAX scores?